Table 2 Selected characteristics of patients at start of follow-up, by analysis cohort
| Â | New-user cohort | Newly-discontinued-user cohort | ||
|---|---|---|---|---|
Discontinued cinacalcet | Did not discontinue | Reinitiated cinacalcet | Did not reinitiate | |
N | 172 | 441 | 171 | 244 |
Age (yrs) | 62.8 (16.9) | 61.9 (15.6) | 63.6 (14.8) | 63.5 (15.8) |
Time on dialysis (yrs) [median/IQR] | 3.9 [1.8, 7.1] | 3.7 [1.7, 7.0] | 5.1 [2.7, 9.6] | 4.5 [2.4, 8.5] |
Male (%) | 60.5 | 62.1 | 52.0 | 58.9 |
Coronary artery disease (%) | 31.6 | 26.1 | 28.2 | 32.9 |
Cancer (%) | 16.4 | 11.7 | 14.8 | 12.6 |
Other cardiovascular disease (%) | 24.0 | 27.1 | 25.9 | 28.9 |
Cerebrovascular disease (%) | 16.5 | 11.2 | 13.6 | 14.2 |
Congestive heart failure (%) | 15.8 | 12.2 | 12.9 | 15.5 |
Diabetes (%) | 28.7 | 29.6 | 27.8 | 31.1 |
GI Bleeding (%) | 2.9 | 3.4 | 4.1 | 5.0 |
Hypertension (%) | 86.5 | 88.5 | 87.6 | 86.3 |
Lung disease (%) | 16.5 | 11.9 | 9.5 | 15.5 |
Psychiatric disorder (%) | 21.6 | 11.5 | 17.1 | 21.8 |
Peripheral vascular disease (%) | 31.6 | 24.8 | 27.6 | 30.1 |
Hospitalized in baseline period (%) | 18.0 | 16.1 | 15.8 | 18.7 |
BMI (kg/m2) | 25.9 (5.3) | 26.5 (5.2) | 26.2 (5.3) | 26.2 (5.4) |
Serum phosphorus (mg/dl) | 5.3 (1.7) | 5.4 (1.5) | 5.1 (1.7) | 5.1 (1.6) |
Serum PTH (pg/ml) [median/IQR] | 430 [317, 749] | 507 [340, 780] | 310 [145, 575] | 237 [117, 518] |
Serum total calcium (mg/dl) | 9.1 (0.9) | 9.3 (0.8) | 9.0 (0.9) | 8.9 (0.8) |
Serum albumin (g/dl) | 3.8 (0.4) | 3.8 (0.5) | 3.8 (0.5) | 3.7 (0.5) |
Phosphate binder use (%) | ||||
 No phosphate binder use | 17.5 | 15.8 | 15.5 | 18.0 |
 Ca-containing only | 7.0 | 12.3 | 13.1 | 11.7 |
 Non-Ca-containing only | 57.9 | 53.3 | 54.2 | 49.4 |
 Both | 17.5 | 18.6 | 17.3 | 20.9 |
Vitamin D (active/analog) use (%) | ||||
 No vitamin D use | 42.9 | 37.5 | 34.5 | 42.3 |
 IV vitamin D only | 29.4 | 30.1 | 31.6 | 27.2 |
 Oral vitamin D only | 25.9 | 32.4 | 32.1 | 29.3 |
 Both | 1.8 | 0.0 | 1.8 | 1.3 |